WHO ICTRP trial
A study of REGN2810 (Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody)…
EUCTR2017-003684-35-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2017-003684-35-DE |
|---|---|
| Public title | A study of REGN2810 (Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in patients with lung cancer |
| Scientific title | A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer |
| Primary sponsor | Regeneron Pharmaceuticals, Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United States;Taiwan;Spain;Austria;United Kingdom;France;Canada;Belgium;Poland;Australia;Germany;Netherlands;Korea, Republic of |
| Conditions | Non-Small Cell Lung Cancer MedDRA version: 20.1 Level: LLT Classification code 10025048 Term: Lung cancer non-small cell recurrent System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Product Name: cemiplimab Product Code: REGN2810 Pharmaceutical Form: Solution for infusion INN or Proposed INN: cemiplimab Current Sponsor code: REGN2810 Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (GDF8) ANTIBODY Concentration… |
| Registration date | Apr 4, 2018 |
| Target size | 201 |
| Secondary IDs | R2810-ONC-1763 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: